Annual report pursuant to Section 13 and 15(d)

Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details)

v3.8.0.1
Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Finite-lived Intangible Assets, Gross $ 43,620 $ 43,620
Finite-lived Intangible Assets, Accumulated Amortization (10,515) (7,262)
Finite-lived Intangible Assets, Net Carrying Value $ 33,105 36,358
Diagnostic Assets, Thyroid [Member] | Asuragen Acquisition [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 9 years  
Finite-lived Intangible Assets, Gross $ 8,519 8,519
Diagnostic Assets, Pancreas Test [Member] | RedPath Acquisition [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 7 years  
Finite-lived Intangible Assets, Gross $ 16,141 16,141
Diagnostic Assets, Barrett's Test [Member] | RedPath Acquisition [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 9 years  
Finite-lived Intangible Assets, Gross $ 18,351 18,351
Diagnostic Lab, CLIA Lab [Member]    
Finite-lived Intangible Asset, Useful Life (Years) 2 years 3 months 19 days  
Finite-lived Intangible Assets, Gross $ 609 609
Diagnostic Assets [Member]    
Finite-lived Intangible Assets, Gross $ 43,011 $ 43,011